posted on 2025-11-25, 17:17authored byMattia Francesco Maria Gerli, Giuseppe Calà, Max Arran Beesley, Beatrice Sina, Lucinda Tullie, Kylin Yunyan Sun, Francesco Panariello, Federica Michielin, Joseph R Davidson, Francesca Maria Russo, Brendan C Jones, Dani Do Hyang Lee, Savvas Savvidis, Theodoros Xenakis, Ian C Simcock, Anna A Straatman-Iwanowska, Robert HirstRobert Hirst, Anna L David, Christopher O’Callaghan, Alessandro Olivo, Simon Eaton, Stavros P Loukogeorgakis, Davide Cacchiarelli, Jan Deprest, Vivian SW Li, Giovanni Giuseppe Giobbe, Paolo De Coppi
Isolation of tissue-specific fetal stem cells and derivation of primary organoids is limited to samples obtained from termination of pregnancies, hampering prenatal investigation of fetal development and congenital diseases. Therefore, new patient-specific in vitro models are needed. To this aim, isolation and expansion of fetal stem cells during pregnancy, without the need for tissue samples or reprogramming, would be advantageous. Amniotic fluid (AF) is a source of cells from multiple developing organs. Using single-cell analysis, we characterized the cellular identities present in human AF. We identified and isolated viable epithelial stem/progenitor cells of fetal gastrointestinal, renal and pulmonary origin. Upon culture, these cells formed clonal epithelial organoids, manifesting small intestine, kidney tubule and lung identity. AF organoids exhibit transcriptomic, protein expression and functional features of their tissue of origin. With relevance for prenatal disease modeling, we derived lung organoids from AF and tracheal fluid cells of congenital diaphragmatic hernia fetuses, recapitulating some features of the disease. AF organoids are derived in a timeline compatible with prenatal intervention, potentially allowing investigation of therapeutic tools and regenerative medicine strategies personalized to the fetus at clinically relevant developmental stages.<p></p>
Correction: Nature Medicine https://doi.org/10.1038/s41591-024-02807-z, published online 4 March 2024.
In the version of this article initially published, there were inconsistences, where in the Methods “AF collection and isolation of the viable cell fraction” paragraph, the first sentence, now reading “AF samples (amniocenteses and amniodrainages) were collected from UCLH FMU and UZ Leuven as part of standard patient clinical care”, was initially preceded by “Euploid,” though the sample contained two chromosomal abnormalities; and in Supplementary Table 1, where for sample code HO680, the sex was listed as female following prenatal clinical data, whereas the sample was identified and processed in further analysis as male. The changes have been made in Supplementary Table 1 and in the HTML and PDF versions of the article.
Raw individual-level data and combined processed data of the bulk RNA sequencing (AFOs, TFOs and fetal tissue-derived organoids) and scRNA-seq (AF and AFOs) have been uploaded to the NCBI Gene Expression Omnibus (GSE220994). These data are openly available with no restriction or time limit. Questions or additional requests can be directed to the corresponding authors. Source data are provided with this paper.